Clinical trial
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory…
NCT00098436 · Vion Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00098436 |
|---|---|
| Title | Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias |
| Official title | A Phase I Study Of Cloretazine™ (VNP40101M) And Temozolomide In Patients With Hematologic Malignancies |
| Lead sponsor | Vion Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | laromustine, temozolomide |
| Enrollment | 25 |
| Start date | Sep 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Aug 1, 2008 |
| First posted | Dec 8, 2004 |
| Last update posted | Jul 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: